3/31
07:00 am
vygr
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
Medium
Report
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
3/20
09:00 pm
vygr
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
Medium
Report
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
3/17
03:03 pm
vygr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
3/13
12:36 pm
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $14.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $14.00 to $12.00. They now have a "buy" rating on the stock.
3/13
08:00 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
3/12
11:01 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) was given a new $10.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
High
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) was given a new $10.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
3/12
10:33 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "outperform" rating re-affirmed by analysts at Wedbush.
3/12
10:12 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/11
04:01 pm
vygr
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Medium
Report
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
3/11
12:19 pm
vygr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
3/10
05:45 pm
vygr
Voyager Therapeutics Q4 2024 Earnings Preview [Seeking Alpha]
Medium
Report
Voyager Therapeutics Q4 2024 Earnings Preview [Seeking Alpha]
3/4
10:39 am
vygr
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer's approach [Yahoo! Finance]
Medium
Report
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer's approach [Yahoo! Finance]
3/4
07:07 am
vygr
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast [Yahoo! Finance]
Low
Report
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast [Yahoo! Finance]
3/4
07:00 am
vygr
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
Low
Report
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
3/3
02:40 pm
vygr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
3/3
11:40 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
3/3
07:00 am
vygr
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
High
Report
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
2/25
05:00 pm
vygr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
2/25
07:00 am
vygr
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
Low
Report
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
2/24
09:00 pm
vygr
VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm
Low
Report
VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm
2/21
10:51 pm
vygr
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Medium
Report
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
2/20
05:40 pm
vygr
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
2/19
06:00 pm
vygr
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors
Low
Report
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors
2/18
05:57 pm
vygr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
2/11
07:17 pm
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $9.00 price target on the stock, down previously from $11.00.
Medium
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $9.00 price target on the stock, down previously from $11.00.